-
1 Comment
Apex Healthcare Berhad is currently in a long term downtrend where the price is trading 7.6% below its 200 day moving average.
From a valuation standpoint, the stock is 68.9% cheaper than other stocks from the Other sector with a price to sales ratio of 2.0.
Apex Healthcare Berhad's total revenue sank by 6.4% to $169M since the same quarter in the previous year.
Its net income has increased by 0.7% to $14M since the same quarter in the previous year.
Finally, its free cash flow grew by 79.1% to $23M since the same quarter in the previous year.
Based on the above factors, Apex Healthcare Berhad gets an overall score of 3/5.
| Exchange | KLSE |
|---|---|
| Industry | Medical Distribution |
| CurrencyCode | MYR |
| ISIN | MYL7090OO003 |
| Sector | Healthcare |
| PE Ratio | 19.55 |
|---|---|
| Target Price | 2.47 |
| Beta | 0.29 |
| Dividend Yield | 4.2% |
| Market Cap | 2B |
Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, distribution, and wholesale of pharmaceutical and healthcare products in Malaysia, Singapore, and internationally. It operates in three segments: Manufacturing, Distribution, and Corporate. The company offers a range of products, including cough mixture and antihistamine, anti-infective, anti-diabetic, anti-hypertensive, neuromuscular agent, analgesic, dermatological, and ophthalmological products in the form of tablets, capsules, oral liquids and suspensions, creams, and sterile eye drops under the Xepa brand name. It also engages in the contract manufacturing of surgical grade orthopedic devices, components, and surgical instruments, as well as orthopedic components that are used in the surgical treatment of musculoskeletal disorders resulting from traumas, diseases, injuries, or deformities. In addition, the company is involved in the retail of pharmaceutical products; rental and management of properties; brand management activities; and provision of accounting and management consultancy services. Further, it commercializes pharmaceuticals, consumer healthcare products, and medical devices under the Zynexis brand name. The company was founded in 1962 and is headquartered in Malacca, Malaysia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 7090.KLSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
